According to the Food and Drug Administration, Azurity Pharmaceuticals Inc. has voluntarily removed a large number of Zenzezi dextroamphetamine sulfate 30-milligram tablets that were being distributed across the country because the drug in the bottle may have been incorrect. It is said that it was recovered.
Zenzedi is used to treat narcolepsy and attention-deficit hyperactivity disorder (ADHD).
Although the tablets were shipped under the Zenzedi label, they may actually contain carbinoxamine maleate, an antihistamine. The problem was discovered when a pharmacist in Nebraska opened a bottle of Zenzedi and found the wrong pill inside. This discovery triggered an investigation and led to a recall.
On January 4, Azurity Pharmaceuticals contacted wholesalers to recall bottles that appeared to contain the wrong pills, although some of the intermediaries had already been distributed at the consumer level. Consumers whose bottles contain the wrong pills must return the bottles to the place of purchase.
Zenzedi's tablet is a yellow hexagon with “30” engraved on one side and “MIA” on the other. But the drug the pharmacist found was a round, white pill with “GL” stamped on one side and “211” on the other, according to the FDA.
Azurity Pharmaceuticals said it is not currently aware of any adverse events related to this issue, but serious problems could occur if patients take the wrong medication.
In general, people who accidentally take antihistamines may experience drowsiness, drowsiness, central nervous system (CNS) depression, increased intraocular pressure, enlarged prostate, urinary tract obstruction, and thyroid problems. People with ADHD or narcolepsy are at even greater risk if they take antihistamines instead of appropriate medications.
“For patients with attention-deficit hyperactivity disorder (ADHD) and narcolepsy (sleep disorders), accidents and injuries caused by the sedative effects of carbinoxamine can lead to continued disability and even death in severe cases, especially for individuals. There is a good chance that the person using it (without knowing that they are not receiving Zenzedi) may engage in activities that require significant concentration and alertness (driving, operating heavy machinery, etc.). ” reads in part the recall announcement.
People with ADHD and narcolepsy clearly aren't taking the medications they need, which can lead to their symptoms being undertreated.
Azurity Pharmaceuticals hired Inmar Intelligence to handle the recall process. For more information about the recall, contact Inmar Intelligence at 1-877-804-2069, Monday through Friday, 9 a.m. to 5 p.m. EST.
